Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/11778
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12481]
Metadata
Show full item record
CONSIDERATIONS ON CLINICAL TRIALS OF LEPROSY TREATMENT: NEED OF NOVEL DRUG COMBINATIONS
Drug combination
Leprosy
Multidrug therapy
Relapse
Resistance
Surrogate end point
Treatment
Author
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Departamento de Dermatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Departamento de Dermatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ, Brasil.
Abstract
Considering that after 30 years of using multidrug therapy (MDT), leprosy
eradication has still not been achieved, leprosy treatment must remain on
the drug discovery agenda. Due to the complexities inherent in leprosy
disease and the many methodological issues involved in clinical trials,
the task of translating the bench findings into clinical practice has been
arduous. While the effectiveness of reducing the currently recommended
MDT remains controversial, a number of highly bactericidal antibiotics
and immune-modulatory drugs have emerged as prospective candidates
to improve patient adherence and quality of life, reduce adverse effects
and prevent resistance. To replace the standard WHO-MDT, the new
combination must be the shortest, simplest and, consequently, most
affordable treatment possible.
Keywords in Portuguese
ResistênciaKeywords
Clinical trialDrug combination
Leprosy
Multidrug therapy
Relapse
Resistance
Surrogate end point
Treatment
Share